Applied Pharmacometrics

  • Stephan Schmidt
  • Hartmut Derendorf

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 14)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Jeffrey Barrett
    Pages 83-108
  3. Liping Zhang, Amit Roy, Marc Pfister
    Pages 109-137
  4. Parag Garhyan, Brian Gregory Topp, Jenny Y. Chien, Vikram P. Sinha, Meindert Danhof, Stephan Schmidt
    Pages 139-159
  5. Anne van Rongen, Margreke J. E. Brill, Jeroen Diepstraten, Catherijne A. J. Knibbe
    Pages 161-187
  6. Joanna Parkinson, Anne S.Y. Chain, Piet H. van der Graaf, Sandra A.G. Visser
    Pages 189-227
  7. Sherwin K. B. Sy, Hartmut Derendorf
    Pages 229-258
  8. George L. Drusano, Ashley N. Brown
    Pages 259-295
  9. Charles Peloquin
    Pages 325-348
  10. Bhargava Kandala, Günther Hochhaus
    Pages 349-382
  11. Anna Georgieva Kondic, Antonio Cabal, Ghassan N. Fayad, Khamir Mehta, Thomas Kerbusch, Teun M. Post
    Pages 383-406
  12. Elizabeth CM de Lange
    Pages 407-449
  13. Brian Corrigan, Kaori Ito, James Rogers, Daniel Polhamus, Diane Stephenson, Klaus Romero
    Pages 451-476
  14. Sujatha Menon, Sriram Krishnaswami
    Pages 477-498
  15. Vivek S. Purohit, Manisha Lamba, Pankaj Gupta
    Pages 499-516
  16. Ping Ji, Jiang Liu, Hao Zhu, Yaning Wang
    Pages 517-537
  17. Maurice G. Emery, Peter C. Haughney, John P. Gibbs
    Pages 539-562
  18. Back Matter
    Pages 563-565

About this book


This comprehensive volume provides an update on the current state of pharmacometrics in drug development. It consists of nineteen chapters all written by leading scientists from the pharmaceutical industry, regulatory agencies and academia. After an introduction of the basic pharmacokinetic and pharmacodynamic concepts of pharmacometrics in drug development, the book presents numerous examples of specific applications that utilize pharmacometrics with modeling and simulations over a variety of therapeutic areas, including pediatrics, diabetes, obesity, infections, psychiatrics, Alzheimer’s disease, and dermatology, among others. The examples illustrate how results from all phases of drug development can be integrated in a more timely and cost-effective process.

Applying pharmacometric decision tools during drug development can allow objective, data-based decision making. At the same time, the process can identify redundant or unnecessary experiments as well as some costly clinical trials that can be avoided. In addition to cost saving by expedited development of successful drug candidates, pharmacometrics has an important economic impact in drug product selection.  Unsuccessful drug candidates can be identified early and discontinued without expending efforts required for additional studies and allocating limited resources. Hence, pharmacometric modeling and simulation has become a powerful tool to bring new and better medications to the patient at a faster pace and with greater probability of success.


modeling pharmacodynamics pharmacokinetics simulation

Editors and affiliations

  • Stephan Schmidt
    • 1
  • Hartmut Derendorf
    • 2
  1. 1.University of Florida, Department of Pharmaceutics, Center for Pharmacometrics & Systems PharmacologyOrlandoUSA
  2. 2.University of Florida, College of Pharmacy, Department of PharmaceuticsGainesvilleUSA

Bibliographic information

  • DOI
  • Copyright Information American Association of Pharmaceutical Scientists 2014
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-1-4939-1303-9
  • Online ISBN 978-1-4939-1304-6
  • Series Print ISSN 2210-7371
  • Series Online ISSN 2210-738X
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Consumer Packaged Goods